Celldex Therapeutics
CLDX
130 hedge funds and large institutions have $183M invested in Celldex Therapeutics in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 17 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.49% less ownership
Funds ownership: 4.37% → 3.88% (-0.49%)
3% less funds holding
Funds holding: 134 → 130 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
28% less call options, than puts
Call options by funds: $577K | Put options by funds: $798K
38% less capital invested
Capital invested by funds: $295M → $183M (-$113M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$7.39M |
| 2 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$4.88M |
| 3 |
BlackRock
New York
|
+$3.65M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.41M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$15.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.67M |
| 4 |
Renaissance Technologies
New York
|
-$4.01M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.43M |
CLDX Hedge Fund Activity: Q2 2017 in Review
130 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2017, worth a combined $183M — down 38% from $295M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CLDX and 14 opened new positions — a net loss of 3 holders — while 41 trimmed existing stakes and 42 added.
The largest buyer was Columbia Wanger Asset Management, adding an estimated $7.39M. The largest seller was Franklin Resources, cutting an estimated $15.5M.
- 130 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2017, down from 134 in Q1 2017.
- Funds reported $183M of Celldex Therapeutics stock for Q2 2017, down 38% quarter-over-quarter.
- 14 funds opened new Celldex Therapeutics positions in Q2 2017 and 17 closed out, a net change of -3 holders.
- The largest Celldex Therapeutics buyer in Q2 2017 was Columbia Wanger Asset Management, an estimated $7.39M added.
- The largest Celldex Therapeutics seller in Q2 2017 was Franklin Resources, an estimated $15.5M sold.
Based on aggregated 13F filings for Q2 2017.